NCT04325035 - The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 28, 2020

Primary Completion Date

September 26, 2024

Study Completion Date

October 30, 2024

Conditions

Cardiogenic Shock

Interventions

DRUG

Istaroxime

Reconstituted istaroxime and lactose lyophilized powder delivered via IV infusion

DRUG

Placebo

Reconstituted placebo (lactose lyophilized powder) delivered via IV infusion

Trial Locations (13)

IRCCS San Raffaele Scientific Institute, Milan

UOC Cardiologia, ASST degli Spedali Civili di Brescia Pizzale Spedali Civili 1, Brescia

Tufts Medical Center, Boston

Hospital Italiano de Bueno Aires, Capital Federal

Santorio Guemes, Capital Federal

Hospital Privado de Rosario, Rosario

Instituto Cardiovascular de Rosario, Rosario

Santorio de la Trinidad Palermo, Buenos Aires

Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria

Uniwersytecki Szpital Kliniczny, Centrum Chorub Serca, Wroclaw

Uniwersytecki Szpital Kliniczny w Białymstoku, Bialystok

Uniwersytecki Szpital Kliniczny w Opolu, Opole

4 Wojskowy Szpital Kliniczny, Wroclaw